{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:28:55Z","timestamp":1759422535515,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD012767"],"award-info":[{"award-number":["R01MD012767"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Patients on anticoagulant\/antiplatelet medications are at a high risk of bleeding following external beam radiation therapy for localized prostate cancer. SBRT may reduce the bleeding risk by decreasing the volume of bladder\/rectum receiving high doses. This retrospective study sought to evaluate the rates of hematuria and hematochezia following SBRT in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Localized prostate cancer patients treated with SBRT from 2007 to 2017 on at least one anticoagulant\/antiplatelet at baseline were included. The minimum follow-up was 3 years with a median follow-up of 72 months. Patients who had a rectal spacer placed prior to SBRT were excluded. Radiotherapy was delivered in 5 fractions to a dose of 35 Gy or 36.25 Gy utilizing the CyberKnife system. Hematuria and hematochezia were prospectively assessed before and after treatment using the Expanded Prostate Cancer Index Composite (EPIC-26). Toxicities were scored using the CTCAE v4. Cystoscopy and colonoscopy findings were retrospectively reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-four men with a median age of 72 years with a history of taking at least one anticoagulant and\/or antiplatelet medication received SBRT. Warfarin (46%), clopidogrel (34%) and rivaroxaban (9%) were the most common medications. Overall, 18.2% experienced hematuria with a median time of 10.5 months post-SBRT. Altogether, 38.6% experienced hematochezia with a median time of 6 months post-SBRT. \u2265 Grade 2 hematuria and hematochezia occurred in 4.6% and 2.5%, respectively. One patient required bladder neck fulguration and one patient underwent rectal cauterization for multiple non-confluent telangiectasia. There were no grade 4 or 5 toxicities. Cystoscopy revealed bladder cancer (40%) and benign prostatic bleeding (40%) as the most common hematuria etiology. Colonoscopy demonstrated hemorrhoids (54.5%) and radiation proctitis (9.1%) as the main causes of hematochezia. There was no significant change from the mean baseline EPIC-26 hematuria and hematochezia scores at any point during follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with baseline anticoagulant usage, moderate dose prostate SBRT was well tolerated without rectal spacing. High grade bleeding toxicities were uncommon and resolved with time. Baseline anticoagulation usage should not be considered a contraindication to prostate SBRT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.722852","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:07:51Z","timestamp":1631858871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Abigail","family":"Pepin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarthak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Pernia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Ayoob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Aghdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.026","article-title":"External Beam Radiotherapy for Prostate Cancer Patients on Anticoagulation Therapy: How Significant Is the Bleeding Toxicity","volume":"76","author":"Choe","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00431-J","article-title":"The Response of the Urinary Bladder, Urethra, and Ureter to Radiation and Chemotherapy","volume":"31","author":"Marks","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.07.1386","article-title":"Radiation Proctopathy in the Treatment of Prostate Cancer","volume":"66","author":"Garg","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct Oral Anticoagulants: Evidence and Unresolved Issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.008","article-title":"A Prospective Evaluation of Rectal Bleeding After Dose-Escalated Three-Dimensional Conformal Radiation Therapy Using an Intrarectal Balloon for Prostate Gland Localization and Immobilization","volume":"67","author":"D\u2019Amico","year":"2006","journal-title":"Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-197","article-title":"Rectal Endoscopy Findings Following Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer","volume":"8","author":"Sood","year":"2013","journal-title":"Radiat Oncol Lond Engl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.09.054","article-title":"It\u2019s All the RAVE: Time to Give Up on the \u201cChronic Radiation Proctitis\u201d Misnomer","volume":"160","author":"Mahmood","year":"2021","journal-title":"Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03852.x","article-title":"Fatal Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Findings From the RIETE Registry","volume":"8","author":"Nieto","year":"2010","journal-title":"J Thromb Haemost JTH"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-Modulated Fractionated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings From an International, Randomised, Open-Label, Phase 3, Non-Inferiority Trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer: The Georgetown University Experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol Lond Engl"},{"key":"B12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1160\/TH13-11-0918","article-title":"New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Impact of Study Design, Double Counting and Unexpected Findings on Interpretation of Study Results and Conclusions","volume":"111","author":"Chan","year":"2014","journal-title":"Thromb Haemost"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v3.i11.351","article-title":"Incidence, Clinical Impact and Risk of Bleeding During Oral Anticoagulation Therapy","volume":"3","author":"Rubboli","year":"2011","journal-title":"World J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results From the Hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199804000-00040","article-title":"The Treatment of Gross Hematuria Secondary to Prostatic Bleeding With Finasteride","volume":"159","author":"Sieber","year":"1998","journal-title":"J Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.14740\/gr1115","article-title":"Acute Lower Gastrointestinal Bleeding in Patients Treated With non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice: Characteristics and Clinical Outcome","volume":"12","author":"Diamantopoulou","year":"2019","journal-title":"Gastroenterol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.02.010","article-title":"Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.011","article-title":"Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation","volume":"15","author":"Flack","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation Dose\u2013Volume Effects of the Urinary Bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-015-0351-6","article-title":"Hematuria Following Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer","volume":"10","author":"Gurka","year":"2015","journal-title":"Radiat Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-014-0277-4","article-title":"Proctitis Following Stereotactic Body Radiation Therapy for Prostate Cancer","volume":"9","author":"Joh","year":"2014","journal-title":"Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.12.010","article-title":"Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer","volume":"94","author":"Musunuru","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","article-title":"Assessment of Risk of Late Rectal Bleeding for Patients With Prostate Cancer Started on Anticoagulation Before or After Radiation Treatment","volume":"34","author":"Schreiber","year":"2014","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.722852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:07:54Z","timestamp":1631858874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.722852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":23,"alternative-id":["10.3389\/fonc.2021.722852"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.722852","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"article-number":"722852"}}